FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study
1998

FEP Regimen for Advanced Gastric Cancer

Sample size: 62 publication Evidence: moderate

Author Information

Author(s): E Bajetta, M Di Bartolomeo, C Carnaghi, R Buzzoni, L Mariani, V Gebbia, G Comella, G Pinotti, G Ianniello, G Schieppati, AM Bochicchio, L Maiorino

Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Hypothesis

Does the addition of low-dose GM-CSF to the FEP regimen increase dose intensity and improve treatment outcomes in advanced gastric cancer?

Conclusion

The FEP regimen is as effective as the EAP regimen for treating advanced gastric cancer, but with fewer complete remissions.

Supporting Evidence

  • The overall response rate was 34%, with only one complete remission.
  • Patients receiving GM-CSF had a significantly higher dose intensity than those who did not.
  • Median survival for all patients was 9 months.

Takeaway

Doctors tested a new treatment for stomach cancer and found it works just as well as an older one, but doesn't help as many people get completely better.

Methodology

This was a multicenter, randomized, parallel-group phase II study comparing the FEP regimen with and without GM-CSF in patients with advanced gastric cancer.

Limitations

The study did not assess long-term survival benefits and was limited by the poor prognostic factors of the patient population.

Participant Demographics

The study included 62 patients, predominantly male (45 males, 17 females), with a median age of 54 years, and most had metastatic disease.

Statistical Information

P-Value

P = 0.0001

Confidence Interval

95% CI 22-46

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication